Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Verastem, Inc. VSTM
$0.41
-$0 (-1.22%)
На 18:00, 12 мая 2023
+1 119.51%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
82609448.00000000
-
week52high
1.47
-
week52low
0.29
-
Revenue
2596000
-
P/E TTM
-1
-
Beta
0.78892700
-
EPS
-0.43000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| RBC Capital | Outperform | 14 апр 2022 г. | |
| Truist Securities | Buy | 09 мар 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 20 июл 2021 г. |
| Alliance Global Partners | Buy | 01 июл 2021 г. | |
| BTIG | Buy | Neutral | 24 мая 2021 г. |
| BTIG | Buy | Buy | 05 окт 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 07 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Calkins Daniel | A | 165000 | 165000 | 27 янв 2023 г. |
| Paterson Dan | A | 1680880 | 1680880 | 27 янв 2023 г. |
| Stuglik Brian M | A | 2216355 | 2216355 | 27 янв 2023 г. |
| Calkins Daniel | D | 98517 | 74 | 05 янв 2023 г. |
| Calkins Daniel | D | 98591 | 1246 | 27 дек 2022 г. |
| Stuglik Brian M | D | 1122520 | 3556 | 19 дек 2022 г. |
| Gagnon Robert E. | D | 574717 | 1429 | 19 дек 2022 г. |
| Paterson Dan | D | 463828 | 2954 | 19 дек 2022 г. |
| Stuglik Brian M | D | 1126076 | 25162 | 16 дек 2022 г. |
| Gagnon Robert E. | D | 576146 | 12408 | 16 дек 2022 г. |
Новостная лента
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
Business Wire
18 апр 2023 г. в 07:05
BOSTON--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will present at the Stifel 2023 Virtual Targeted Oncology Days on Tuesday, April 25, 2023 at 2:30 p.m. ET. A live webcast of the presentation will be available on the investors section of the Company's website at www.verastem.com.
7 Very Undervalued Penny Stocks to Buy in April 2023
InvestorPlace
06 апр 2023 г. в 17:39
Investors are attracted to penny stocks for their potential to provide exponential gains. It is very common to find such companies trading for fractions of their target price.
Top 3 stocks under $1 to buy in March
Finbold
14 мар 2023 г. в 09:26
With the third month of 2023 already well underway, the ripple effect from the collapse of multiple banks in the United States is felt far and wide, leaving investors to wonder which stocks are worthy of their attention but often disregarding those obtainable for less than a dollar.
Verastem (VSTM) Upgraded to Strong Buy: What Does It Mean for the Stock?
Zacks Investment Research
30 янв 2023 г. в 13:33
Verastem (VSTM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.